Actemra may reduce scleroderma skin thickening

The interleukin-6 inhibitor tocilizumab (Actemra) substantially reduced skin thickening in patients with systemic sclerosis in the “proof-of concept” faSScinate trial, the results of which have now been published in the Lancet. The mean change in the primary endpoint of a modified Rodnan skin...
Source: Skin and Allergy News - Category: Dermatology Source Type: news